AML and MDS MATTER

Clinicians specializing in pathology and hematology/oncology face challenges in managing acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), similar but distinct blood cancers associated with significant morbidity and mortality that affect many patients in the Unites States (US). ASCP is a long-standing, proud partner in collaborations designed to meet the needs of multidisciplinary care teams on the optimal diagnosis and classification of both AML and MDS, in addition to addressing issues of risk stratification and individualized treatment selection, assessment of treatment responses, monitoring for and mitigation of adverse events, and sharing stories from patients and caregivers regarding their journey.